Moderna Targets 2021 Back-To-School Season For Pediatric Data On COVID-19 Vaccine
Executive Summary
Sponsors are moving to younger populations as the adult clinical trials near enrollment goals; Moderna’s CEO says data in children younger than 12 will be slow to emerge.
You may also be interested in...
US FDA Still Discussing Ideas For Pediatric Development Of COVID-19 Vaccines
J&J CEO Gorsky says the agency is working with sponsors to ensure the proper data is gathered to make the vaccine available in children.
COVID-19 Vaccines: Pediatric Effectiveness Bridging Not Dependent Upon Immune Correlates
Ability to bridge from adult effectiveness data to children in the absence of an identified correlate of protection could be affected by proposed dosing regimen and expected similarity in pediatric response, US FDA official says.
Adolescent Recruitment For COVID-19 Vaccine Trials Is Worry For Operation Warp Speed
However, recruitment for adult trials remains robust, OWS’ Slaoui says.